Invitation to Cosmo’s Investor Day and Full-Year 2023 Webcast Zurich, 20 March 2024
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET.
Invitation to Cosmo’s Investor Day and Full-Year 2023 Webcast Zurich, 20 March 2024
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET.
Cosmo Pharmaceuticals and Medtronic forge ahead in AI-driven care
Agreement expands partnership between Cosmo Pharmaceuticals and Medtronic, set to transform endoscopy with cutting-edge AI technology
Cosmo Pharmaceuticals (“Cosmo”) announces that its subsidiary Cosmo Intelligent Medical Devices has entered into a definitive agreement to expand its partnership with Medtronic plc (NYSE: MDT), a global leader in healthcare technology. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable healthcare advancements for patients and caregivers globally. Through this exclusive global partnership, Medtronic and Cosmo Pharmaceuticals remain committed to revolutionizing endoscopy by harnessing the power of AI to improve patient outcomes. This strategic alliance reinforces Medtronic’s position in AI-integrated healthcare solutions and represents a significant leap in incorporating AI into endoscopic care.
Cosmo confirms full redemption in cash of €175m Convertible Bonds
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash.
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
Cosmo Pharmaceuticals N.V. (“Cosmo”), a leading pharmaceutical company dedicated to enhancing the lives of individuals suffering from acne, is delighted to announce a pivotal step forward in its mission. Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) to the European Medicine Agency (EMA) through the centralized procedure, aimed at obtaining a single Marketing Authorization for the product in the European Union.
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (“Hikma”) today announced the signing of a license agreement for Winlevi® (clascoterone) cream 1% in the Middle East and North Africa (MENA) region (Kingdom of Saudi Arabia, Jordan, Egypt, Morocco, Algeria, Tunisia, Sudan, Iraq, Lebanon, United Arab Emirates, Qatar, Kuwait, Oman, Bahrain, Yemen, Libya, and Syria).
Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (“Glenmark”), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
Termination of Agreement for Rifamycin SV MMX®with Dr. Falk Pharma
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the termination by mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX® in the EU and other selective countries.
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Adalvo Ltd. (“Adalvo”) today announced the signing of a license and supply agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA) and Latin America (LATAM) regions.
Cosmo presents strong H1 2023 operational and financial results
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its financial results for H1 2023, including revenues of €43.7 million (H1 2022: €41.5 million), EBITDA of €14.0 million (H1 2022: €14.9 million), an operating profit of €7.1 million (H1 2022: €8.1 million) and a profit before tax €3.7 million (H1 2022: €9.1 million).
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wednesday, 26 July 2023 at 07:00 am CEST.
dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz